Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review.

Jafri SH, Shi R, Mills G. · 2013

Read Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. by Jafri SH, Shi R, Mills G. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3618002.txt.

Description

Syed Jafri, Runhua Shi, and Glenn Mills tested a simple inflammation score in lung cancer in BMC Cancer in 2013. Body-wide inflammation tracks with cancer growth, wasting, and poor outcomes. Their score, the Advanced Lung Cancer Inflammation Index, multiplies body mass index by blood albumin and divides by the ratio of two white cell types, all routine values. The team checked records of 173 patients with metastatic non-small cell lung cancer diagnosed at one center between 2000 and 2011.

Patients scoring below eighteen, the high-inflammation group, carried more spread sites and worse fitness, and fewer received chemotherapy. Their cancer stayed quiet for a median 2.4 months and they lived a median 3.4 months, against 5.1 and 8.3 months in the low-inflammation group. After adjusting for other factors, the low score still predicted worse survival. A free score from standard labs, the authors argue, can flag patients needing closer attention.

Catalog record

CREATORJafri SH, Shi R, Mills G.
YEAR2013
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3618002

Browse the full library · About the Tower of Babel